Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Inclusion Criteria: * More than or equal to 18 years of age, at the time of signing the informed consent. * Hemoglobin: Stable Hemoglobin 9.0 - 11.5 gram per deciliter (g/dL). * Dialysis frequency: On hemodialysis (HD, hemofiltration or hemodiafiltration) three to five times weekly for at least 4 weeks prior to Day -28 Screening through Day 29. * Dialysis adequacy: A single pool Kt/Vurea of \>=1.2 based on a historical value obtained within the prior three months in order to ensure the adequacy of dialysis. If Kt/Vurea is not available, then an average of the last 2 values of urea reduction ratio (URR) of at least 65 percent. NOTE: Only needs confirming at Day -28. * Erythropoiesis-stimulating agent (ESA)dose: Treated with the same ESA (epoetins or their biosimilars, or darbepoetin or methoxy polyethylene glycol \[PEG\]-epoetin beta) with total weekly dose varying by no more than 50 percent during the 4 weeks prior to Day -28. * Iron replacement therapy: Subjects may be on stable maintenance oral or intravenous (IV) (\<=100 milligram (mg)/week) iron supplementation. If subjects are on oral or IV iron, then doses must be stable for the 4 weeks prior to Day -28, during the screening phase, and through the 29 days of treatment. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in study protocol. Exclusion Criteria: * Dialysis modality: Planned change from HD to peritoneal dialysis within…